BRCA1 PROTEIN;
BRCA2 PROTEIN;
PROTEIN P53;
RALOXIFENE;
TAMOXIFEN;
BREAST CANCER;
CANCER EPIDEMIOLOGY;
CANCER RISK;
CANCER SCREENING;
FAMILIAL CANCER;
FAMILY HISTORY;
GENE MUTATION;
GENETIC SCREENING;
HETEROZYGOTE;
HIGH RISK PATIENT;
HORMONE SUBSTITUTION;
HUMAN;
MAMMOGRAPHY;
NATIONAL HEALTH ORGANIZATION;
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT INFORMATION;
POSTMENOPAUSE;
PRACTICE GUIDELINE;
PRIMARY MEDICAL CARE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
SALPINGOOOPHORECTOMY;
SHORT SURVEY;
SOCIAL SUPPORT;
TUMOR SUPPRESSOR GENE;
BREAST NEOPLASMS;
FEMALE;
HETEROZYGOTE;
HUMANS;
MALE;
PRACTICE GUIDELINES AS TOPIC;
Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 14 and 41
National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 14 and 41. (Clinical guideline 164.) 2013. http://guidance.nice.org.uk/CG164.
Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care
National Institute for Health and Care Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. (Clinical guideline 14.) 2004. http://guidance.nice.org.uk/CG14.
Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care
National Institute for Health and Care Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. (Clinical guideline 41.) 2006. http://guidance.nice.org.uk/CG41.
Early and locally advanced breast cancer: Diagnosis and treatment
National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and treatment. (Clinical guideline 80.) 2009. http://guidance.nice.org.uk/CG80.
Public Health and Primary Care, University of Cambridge
Public Health and Primary Care, University of Cambridge. BOADICEA: BOADICEA is a computer program that is used to estimate BRCA1/BRCA2 mutation carrier probabilities and breast/ovarian cancer risks on the basis of family history. http://ccge.medschl.cam.ac.uk/boadicea/.
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing
Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-7.
A breast cancer prediction model incorporating familial and personal risk factors
DOI 10.1002/sim.1668
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30. (Pubitemid 38477070)
Protocols for the surveillance of women at higher risk of developing breast cancer
NHS Breast Screening Programme. Protocols for the surveillance of women at higher risk of developing breast cancer. (NHSBSP Publication No 74). 2013. www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp74.pdf.
